Ketorolac

Ketorolac is a nonsteroidal anti-inflammatory drug, or NSAID, of the acetic acid group, chemically a pyrrolizine carboxylic acid derivative usually formulated as ketorolac tromethamine ^[1]. It is a racemic compound and is distinguished within its class by potent analgesic activity, which is the main reason it is used ^[1]. Rather than being taken for long-term inflammatory conditions like many NSAIDs, it is reserved for the short-term relief of acute pain ^[1].

The drug was patented in 1976 and approved in the United States in 1989, where it is best known under the brand name Toradol ^[1]. An ophthalmic form followed under the name Acular in 1992, and an intranasal spray, Sprix, was approved in 2010 ^[1]. Concerns about gastrointestinal and kidney complications led to its withdrawal from the German market in 1993 and shaped tighter dosing guidance elsewhere ^[1].

Ketorolac is used chiefly for moderate to severe pain, particularly after surgery and injury, and it is frequently given by intramuscular or intravenous injection ^[1]. In hospital and emergency settings it has been shown to relieve pain from conditions such as renal colic, migraine, and musculoskeletal injury about as effectively as commonly used opioids, and it serves as a valuable opioid-sparing agent within multimodal, opioid-reducing pain regimens ^[1][2]. It is also used in infants and children in the perioperative period as a non-opioid analgesic, and ophthalmic drops are used for eye pain and inflammation and for ocular itching ^[2][3].

Mechanistically the drug blocks cyclooxygenase and thereby the synthesis of prostaglandins, which underlies both its strong analgesia and its characteristic risks ^[1]. Its unusually powerful pain relief has made it a useful alternative or adjunct to opioids ^[1][2].

The defining caution with ketorolac is that its use should be brief, generally not beyond a few days, because the risk of serious adverse effects rises steeply with prolonged or high-dose treatment, especially in older adults ^[1]. These effects include gastrointestinal ulceration and bleeding, acute kidney injury that is usually reversible on stopping the drug, and an increased tendency to bleed; like other NSAIDs it also carries cardiovascular and allergic risks and is avoided in people with active ulcers, significant kidney impairment, or bleeding tendencies and in late pregnancy ^[1]. Used within its guidelines it offers effective, opioid-comparable pain relief ^[1].

Ketorolac is a prescription NSAID intended only for short courses of five days or less. It carries boxed warnings for gastrointestinal bleeding and ulcers, kidney injury, bleeding risk and cardiovascular events, and it is contraindicated in advanced kidney disease, active bleeding, before major surgery and during labor. It should not be combined with other NSAIDs or aspirin, and it increases bleeding risk with anticoagulants. Older adults and those with dehydration or kidney problems need extra caution.

Ketorolac increases bleeding time independently of its effects on warfarin pharmacokinetics; in controlled studies, ketorolac prolonged template bleeding time by approximately 35% compared with placebo despite causing no significant change in warfarin pharmacokinetics or prothrombin time ^[5]. This is a pharmacodynamic interaction at the level of platelet function and bleeding risk. Clinical caution is warranted with concurrent warfarin use despite the lack of pharmacokinetic displacement, as the additive antiplatelet effect increases bleeding risk.

Ketorolac, like all NSAIDs, is known to reduce renal function and interact with renal-dependent drugs, particularly relevant with lithium and ACE inhibitors, though specific ketorolac studies at therapeutic doses are limited. NSAIDs have been documented broadly to reduce the renal clearance of lithium and to blunt the antihypertensive effect of ACE inhibitors through renal hemodynamic changes. Concurrent use with other NSAIDs, aspirin at therapeutic doses, and corticosteroids remains understudied for ketorolac specifically.

Checking a whole stack? Run it through interactions + stacks.

Ketorolac, chemically a pyrrolizine carboxylic acid derivative, was developed by the pharmaceutical company Syntex and introduced for clinical use around 1989 to 1990, initially in an injectable form for the treatment of moderate to severe acute pain. It distinguished itself among nonsteroidal anti-inflammatory drugs by the unusual strength of its analgesic action, which in the postoperative setting approaches that of opioids such as morphine. This property made it valuable as a means of relieving surgical pain while sparing opioid use and the side effects that accompany it.

Over time, additional formulations broadened its reach, including an ophthalmic solution (Acular) for ocular inflammation and pain and a nasal spray (Sprix) for short-term systemic analgesia. Recognition that its risks of gastrointestinal bleeding, kidney injury, and impaired platelet function rise sharply with prolonged use led regulators to restrict treatment to short courses, typically no more than five days. Within that boundary it has become a widely used component of modern multimodal, opioid-sparing pain management.

Ketorolac is well regarded as one of the most powerful non-opioid analgesics available, occupying an important place in postoperative and acute-pain care. Its central appeal is the ability to deliver opioid-level relief without the sedation, respiratory depression, and dependence risk that accompany narcotics, and studies show it can substantially reduce opioid requirements when used alongside them. This makes it a valued pillar of the multimodal, opioid-sparing analgesic strategies that have become standard in enhanced-recovery surgical pathways.

Its onset may lag slightly behind an opioid, but its effect often lasts longer. The honest limitation is that the same prostaglandin blockade responsible for its analgesia also raises the risks of gastrointestinal irritation and bleeding, kidney stress, and impaired platelet function, which is precisely why its use is deliberately confined to short courses. Used briefly and appropriately, it is a highly effective tool for controlling significant pain.